



## **GRADUATE CERTIFICATE IN HEALTH PRODUCTS REGULATION**

### **GMS5007 Regulation of Generic Medicines**

*09 May 2022 – 13 May 2022*

### **WORKSHOP PROGRAMME**

---

#### **Learning outcomes**

- Explain the principles and regulatory requirements for a generic medicinal product and the differences from an innovator product
- Describe the fundamental principles for evaluating quality and clinical aspects of a generic medicine
- Describe contemporary approaches and considerations for assessing bioequivalence of different dosage forms
- List the initiatives that are promoting efficiency and effectiveness through regulatory cooperation

## Graduate Certificate in Health Products Regulation

### GMS5007 Regulation of Generic Medicines

**09 – 13 May 2022**

#### Day 1 – 09 May, Mon

Topic		Speaker/ Organisation
9.00am	<b>Zoom Briefing</b>	<b>Mr Osman Bin Mohamad</b> Senior Associate Centre of Regulatory Excellence (CoRE) Duke-NUS Medical School
9.30am	<b>Workshop Briefing</b>	<b>Asst Prof James Leong</b> Head of Pharmaceutical Regulatory Science Programme CoRE, Duke-NUS Medical School
10.30am	<b>Refreshment Break</b>	
<b>Session 1: Regulatory Management of Generic Medicines</b>		
11.00am	<b>Regulatory guidelines for generics</b> <ul style="list-style-type: none"> <li>Key references for submission and evaluation of generics</li> </ul>	<b>Dr Henrike Potthast</b> Biopharmaceutics Expert Pharmacokinetics Federal Institute for Drugs and Medical Devices (BfArM) Germany
11.45am	<b>Dossier requirements for generics</b> <ul style="list-style-type: none"> <li>ICH CTD and ACTD</li> <li>ASEAN Technical Guidelines</li> </ul>	<b>Ms Tan Mui Kiat</b> Principal Assistant Director Generic Medicines Section National Pharmaceutical Regulatory Agency (NPRA), Malaysia
12.30pm	<b>Lunch</b>	
2.00pm	<b>Regulatory frameworks for generics</b> <ul style="list-style-type: none"> <li>Overview of the regulatory requirements of major regulators and Asia Pacific region</li> </ul>	<b>Mr Jin Shun</b> Head, Regulatory Affairs APMA Sandoz
3.00pm	<b>Refreshment Break</b>	
3.30pm	<b>Challenges in regulatory management of generics</b> <ul style="list-style-type: none"> <li>Different dosage forms</li> <li>Divergence in requirements</li> <li>Infringement of patents and IP</li> </ul>	
4.15pm	<b>Networking</b>	
5.00pm	<b>End</b>	

## Day 2 – 10 May, Tue

	Topic	Speaker/ Organisation
9.00am	Individual and Group assessment I	
10.00am	Refreshment Break	
<b>Session 2: Quality Requirements and Assessment of Generics</b>		
10.30am	Guidelines and regulatory requirements for quality aspects of generics	
<b>11.15am</b>	<b>In-Vitro Dissolution studies</b> <ul style="list-style-type: none"> <li>Utility of dissolution studies for assessment of generics</li> <li>Design and dissolution procedures</li> </ul>	<b>Ms Leanne Cornell</b> Senior Evaluator Pharmaceutical Chemistry Section Scientific Evaluation Branch Medicines Regulation Division Therapeutic Goods Administration (TGA), Australia  <b>Ms Ji Wenjie</b> Pharmaceutical Chemistry Section Scientific Evaluation Branch Medicines Regulation Division Therapeutic Goods Administration (TGA), Australia
12.30pm	Lunch	
1.30pm	<b>In-Vitro Dissolution studies (cont'd)</b> <ul style="list-style-type: none"> <li>Dissolution conditions for various dosage forms, including modified release</li> </ul>	<b>Ms Leanne Cornell</b> <b>Ms Ji Wenjie</b> TGA
2.15pm	Briefing for Practicum 1	
2.30pm	Refreshment Break	
3.00pm	<b>Practicum 1</b> <ul style="list-style-type: none"> <li>Evaluation of quality data for regulatory approval</li> </ul>	
4.30pm	Group presentation and Discussion for Practicum 1	
5.30pm	End	

### Day 3 – 11 May, Wed

	Topic	Speaker/ Organisation
9.00am	Individual and Group assessment II	
10.00am	Refreshment Break	
<b>Session 3: Clinical Requirements and Assessment of Generics</b>		
10.30am	Guidelines and regulatory requirements for clinical aspects of generics	<b>Dr Jan Welink</b> Senior Clinical Assessor Dutch Medicines Evaluation Board (MEB), Netherlands
11.00am	Assessing Bioavailability and Bioequivalence (BABE) <ul style="list-style-type: none"> <li>• Study Designs</li> <li>• Evaluation of BABE, including modified release dosage forms</li> </ul>	<b>Dr Jan Welink</b> MEB
12.30pm	Lunch	
1.30pm	Bioanalytical studies for assessing BABE <ul style="list-style-type: none"> <li>• Standards, calibration and controls</li> <li>• Methods and Validation</li> </ul>	<b>Dr Jan Welink</b> MEB
2.15pm	Briefing for Practicum 2	
2.30pm	Refreshment Break	
3.00pm	Practicum 2 <ul style="list-style-type: none"> <li>• Assessment of BABE data for regulatory approval</li> </ul>	
4.30pm	Group presentation and Discussion for Practicum 2	
5.30pm	End	

## Day 4 – 12 May, Thurs

	Topic	Speaker/ Organisation
9.00am	Individual and Group Assessment III	
10.00am	Refreshment Break	
<b>Session 4: Advanced Approaches and Different Dosage Forms</b>		
10.30am	Overview of dosage forms in generic medicines development	<b>Dr Henrike Potthast</b> Biopharmaceutics Expert Pharmacokinetics Federal Institute for Drugs and Medical Devices (BfArM) Germany
11.00am	Approaches and challenges for different dosage forms <ul style="list-style-type: none"> <li>• Orodispersible tablets</li> <li>• Transdermal patches and topicals</li> <li>• Inhalers and nasal sprays</li> <li>• Depot injections</li> </ul>	<b>Dr Henrike Potthast</b> BfArM
12.30pm	Lunch	
1.30pm	BCS-based Biowaivers <ul style="list-style-type: none"> <li>• Guidelines and recommendations</li> <li>• Technical and documentary requirements</li> </ul>	<b>Dr Henrike Potthast</b> BfArM
2.15pm	Briefing for Practicum 3	
2.30pm	Refreshment Break	
3.00pm	Practicum 3 <ul style="list-style-type: none"> <li>• BCS waivers to support regulatory decisions</li> </ul>	
4.30pm	Group presentation and Discussion for Practicum 3	
5.30pm	End	

## Day 5 – 13 May, Fri

	Topic	Speaker/ Organisation
9.00am	End-of-Module (EOM) Assessment	
10.00am	Review of EOM Questions	
10.30am	Break	
<b>Session 5: Improving the Regulatory Management of Generics</b>		
11.00am	<b>Contemporary issues in generic medicines development</b> <ul style="list-style-type: none"> <li>Patent enforcement and Intellectual Property</li> <li>Trends in generics product developments</li> </ul>	<b>Dr Stefanie Amend-Mall</b> Global Program Lead, CN and APAC Sandoz Small Molecules Product Development Sandoz
11.45am	<b>ACSS Consortium – Regional Collaborations for Generics</b>	<b>Dr Michael Harding</b> Principal Evaluator Pharmaceutical Chemistry Section Scientific Evaluation Branch Medicines Regulation Division Therapeutic Goods Administration (TGA), Australia
12.30pm	Lunch	
1.30pm	<b>Case Discussion</b> <ul style="list-style-type: none"> <li>Considerations for Sampling</li> </ul>	
2.30pm	<b>Case Discussion</b> <ul style="list-style-type: none"> <li>Sampling and Regulatory actions for quality deviations of generics</li> </ul>	
3.30pm	Break	
4.00pm	<b>Business and regulatory strategy for developing generics</b>	<b>Dr Krishna Prasad</b> Abbott
4.45pm	<b>Graduate Certificate Workshop Conclusion</b>	<b>A/Prof Silke Vogel</b> Deputy Director, CoRE Senior Associate Dean Graduate Studies Duke-NUS Medical School
5.00 pm	End	